New drug news: Resolvyx RX-10045
Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting
In an oral presentation, Resolvyx and its collaborators reported new data on the company’s lead development candidate, RX-10045. RX-10045 is currently in development to treat dry eye, a disease that affects more than 30 million people in the US. This study showed that RX-10045 promotes tissue repair in human corneal epithelial cells in vitro in a dose dependent manner. This finding may expand the potential benefits of the compound beyond its previously reported anti-inflammatory effects. RX-10045 is currently being evaluated in a randomized, controlled clinical trial in patients with chronic dry eye. The trial is fully enrolled and the last patient is anticipated to complete dosing in May 2009.